Nasal spray could ease stage fright for social anxiety sufferers
NCT ID NCT04754802
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial tested whether a low-dose nasal spray called PH94B can quickly reduce anxiety in adults with social anxiety disorder when they have to speak in public. 224 participants used the spray or a placebo 20 minutes before a short speech and rated their distress. The study aims to see if PH94B offers a fast, non-sedating option for managing acute anxiety in stressful social situations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PH94B nasal spray
What this could lead to
If it works, this could provide a fast-acting, on-demand treatment for anxiety during stressful situations like public speaking for people with social anxiety disorder.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The effect may be modest or no better than placebo, and the spray only targets acute episodes, not the underlying disorder.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VistaGen Clinical Site
Los Angeles, California, 90024, United States
-
VistaGen Clinical Site
Orange, California, 92868, United States
-
VistaGen Clinical Site
Riverside, California, 92503, United States
-
VistaGen Clinical Site
San Diego, California, 92103, United States
-
VistaGen Clinical Site
San Jose, California, 95124, United States
-
VistaGen Clinical Site
Sherman Oaks, California, 91403, United States
-
VistaGen Clinical Site
Jacksonville, Florida, 32256, United States
-
VistaGen Clinical Site
Orlando, Florida, 32801, United States
-
VistaGen Clinical Site
Tampa, Florida, 33614, United States
-
VistaGen Clinical Site
Chicago, Illinois, 60640, United States
-
VistaGen Clinical Site
Watertown, Massachusetts, 02472, United States
-
VistaGen Clinical Site
Princeton, New Jersey, 08540, United States
-
VistaGen Clinical Site
New York, New York, 10128, United States
-
VistaGen Clinical Site
Oklahoma City, Oklahoma, 73106, United States
-
VistaGen Clinical Site
Allentown, Pennsylvania, 18104, United States
-
VistaGen Clinical Site
Media, Pennsylvania, 19063, United States
-
VistaGen Clinical Site
Houston, Texas, 77030, United States
-
VistaGen Clinical Site
San Antonio, Texas, 78229, United States
-
VistaGen Clinical Site
Woodstock, Vermont, 05091, United States
-
VistaGen Clinical Site
Bellevue, Washington, 98007, United States
-
VistaGen Clinical Sites
Fort Myers, Florida, 33912, United States